昊帆生物：公司的多肽合成试剂等化学试剂，主要用于酰胺键的化学合成

Group 1 - The core patent for Semaglutide will expire in March next year, which may have a positive impact on the company's operations [1] - Haofan Bio (301393.SZ) stated that its main products include peptide synthesis reagents and general molecular building blocks, primarily used for the chemical synthesis of amide bonds [1] - The company's operations are influenced by various factors including downstream demand fluctuations, price volatility, industry competition, and capacity layout [1]